XNAS · ADPT
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Adaptive Biotechnologies Corporation Common Stock

Adaptive Biotechnologies Corporation Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$25.99
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Analyst data unavailable at compute time
ADPT
Adaptive Biotechnologies Corporation Common Stock
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ADPT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ADPT catalysts
About Adaptive Biotechnologies Corporation Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2019
Employees
624
Country
US

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$25.99
Last session
Day high
$25.99
Last session
Day low
$25.99
Last session
Previous close
$25.99
52W high
$25.99
0.00% from high
52W low
$12.41
100% of range
Market cap
$4.1B
EPS
$-0.4900
Beta
1.61
Shares out
159.6M
Avg volume
2.6M
VWAP
$25.99
Last session
Price history computed in-house
1W
+4.93%
1M
+16.70%
3M
+83.93%
1Y
+99.92%
YTD
+60.04%
SMA 50 $22.01 · above
SMA 200 $17.17 · above
52W position 100%

ADPT overview

Loading financial statements
Loading ADPT Form 4 filings
Public disclosures

Congress activity in ADPT

No receipt-qualified Congressional disclosure is present for ADPT in the cached public ledger.

Federal contracts

ADPT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ADPT in this window.
Lobbying spend

ADPT lobbying filings, year to date.

Registered lobbying filings matched to Adaptive Biotechnologies Corporation Common Stock.

$370.0K
Refresh interval: 12hSource: LDA disclosure filings
Trade (domestic/foreign)
Filing
$140.0K
APTIV PLC

APTIV, PLC

Apr 10, 2026
Filing
$130.0K
APTIV PLC

APTIV, PLC

Jan 20, 2026
Filing
$100.0K
APTIV PLC

APTIV, PLC

Jul 15, 2026
Loading news for ADPT
Analyst ratings
Sovereign unlock shows live analyst consensus for ADPT.
Options
Sovereign unlock shows live options positioning for ADPT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.